Completed

Fused PET-CT Dataset for Improved Resection Accuracy in Advanced Colorectal Cancer

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This phase 2 study aims to evaluate the accuracy of a handheld probe in detecting the precise position of advanced colorectal cancer using a combined PET-CT dataset, with the goal of improving surgical resection accuracy.

What is being tested

Whole Body PET Scan

+ Abdomen and Pelvis CT Scan

+ Fludeoxyglucose F 18 Radiation Therapy

ProcedureRadiation
Who is being recruted

Urogenital Diseases+19

+ Urinary Bladder Diseases

+ Colonic Diseases

Over 18 Years
See all eligibility criteria
How is the trial designed

Diagnostic Study

Phase 2
Interventional
Study Start: March 2004
See protocol details

Summary

Principal SponsorOhio State University Comprehensive Cancer Center
Last updated: March 2, 2016
Sourced from a government-validated database.Claim as a partner

Study start date: March 1, 2004

Actual date on which the first participant was enrolled.

PRIMARY OBJECTIVES: I. To determine the feasibility of rigidly (linearly) registering PET to CT images and applying this fused dataset to guide surgery with an image-guided navigation system and a handheld positron probe in order to facilitate disease detection and improve resection accuracy in advanced stage colorectal cancer. II. To complete development of software for the nonlinear registration of PET and CT datasets. OUTLINE: Patients undergo preoperative whole-body PET scans and CT scans of the abdomen and pelvis. Patients then receive 18 F fludeoxyglucose (FDG) intravenously (IV) 60-90 minutes prior to surgery and undergo intraoperative CT scans using a handheld probe and computer navigation system.

NCT01821105
Principal SponsorOhio State University Comprehensive Cancer Center
Last updated: March 2, 2016
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

21 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Diagnostic Study

Diagnostic studies focus on improving how we detect or confirm a disease. They test new tools or techniques that could provide faster or more accurate diagnoses.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesUrinary Bladder DiseasesColonic DiseasesDigestive System DiseasesDigestive System NeoplasmsFemale Urogenital Diseases and Pregnancy ComplicationsGastrointestinal DiseasesGastrointestinal NeoplasmsIntestinal DiseasesIntestinal NeoplasmsNeoplasmsNeoplasms by SiteRectal DiseasesUrogenital NeoplasmsUrologic DiseasesUrologic NeoplasmsFemale Urogenital DiseasesMale Urogenital DiseasesUrinary Bladder NeoplasmsColonic NeoplasmsRectal NeoplasmsColorectal Neoplasms

Criteria

Inclusion Criteria: Patients with histologically-confirmed colorectal carcinoma and preoperative PET scan with evidence of hypermetabolic lesions suspicious for cancer will be eligible for this study. In cases of primary cancer, there must be a tissue-confirmed diagnosis. In recurrent cases, patients must have clinical evidence by CT or MRI of disease suitable for resection. Patients must be candidates for clinically indicated surgery. Patients with recurrent disease may have had prior surgery and/or chemotherapy with no limit to the number of prior therapeutic procedures or chemotherapeutic regimens. Patients must have a performance status of 0, 1 or 2 by ECOG(Eastern Cooperative Oncology Group)standards. Patients must give written informed consent including consent to have IV line placed for FDG administration. Patients must be at least 18 years of age. Children under the age of 18 are excluded from the study due to the rarity of colorectal cancer in children. Because radiolabeled agents are known to be teratogenic, women of child-bearing potential and men must agree to use an acceptable form of contraception prior to study entry and for the duration of the study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Organ function requirements: Patients must have organ and marrow function adequate to undergo laparotomy. Specifically: Serum creatinine < 2.0 mg/dl Serum bilirubin < 2.0 mg/dl AST(aspartate aminotransferase,serum glutamate oxaloacetate transaminase, serum glutamate oxaloacetate transaminase,serum glutamate pyruvate transaminase)[SGOT]/ALT[SGPT]<4 times institutional upper limit of normal Total WBC(white blood cell)>4,000/mm3 or ANC(absolute neutrophil count)> 1,500/mm3 Platelets > 100,000/mm3 Hgb >10g/dl Patient must have no clinically significant cardiac disease (New York Heart Association Class III/IV); no serious infection requiring treatment with antibiotics; no other serious ill-ness or illness requiring the use of steroids; no clinically significant pulmonary disease or other illness that would contraindicate or increase the risk of complications at surgery. Fasting blood sugar less than 120 mg/dl Exclusion Criteria: Patients with active CNS (central nervous system)tumor involvement are ineligible. Any patient who has retained childbearing potential will not be pregnant or lactating and must use adequate contraception to assure avoidance of conception. Body size prohibits use of the diagnostic equipment (portable CT scanner). Tumor burden is so great (as determined by preoperative PET scanning or intraoperative findings) that further surgery is not advised. If lesions are detected with preoperative CT but not with PET scanning (in other words, all patients will have a positive PET scan as part of the inclusion criteria).

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Patients undergo preoperative whole-body PET scans and CT scans of the abdomen and pelvis. Patients then receive fluoro-deoxyglucose (FDG)IV 60-90 minutes prior to surgery and undergo intraoperative CT scans using a handheld probe and computer navigation system.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Ohio State University Medical Center

Columbus, United StatesOpen Ohio State University Medical Center in Google Maps
CompletedOne Study Center